<h3>Background</h3> Although mortality rates related with Chikungunya (CHIK) outbreaks into Latin America’s endemic-dengue rural and new urban regions are low, dealing with symptoms and sequelae can produce both a significant burden of disease and diminish quality of life — from many months to years — after the acute phase of infection, with a significant impact on public and individual health. <h3>Objectives</h3> The aim of this work was to establish a PANLAR-ACCAR consensus on diagnosis and treatment of CHIK-related inflammatory arthropathies transmitted by Ae. Aegypti and Ae. Albopictus in Latin America (LA). <h3>Methods</h3> Based on the Consensus Development Conference format, a panel of ACCAR rheumatologists (n=10) took part in this PANLAR initiative. Experts voted recommendations from a previous content analysis of the medical literature on CHIK, four subsequent topic’s Conferences and a workshop. Consensus represents the majority agreement (≥80%) achieved for each recommendation. <h3>Results</h3> The panel reach four overarching principles: 1) CHIK virus (CHIKV) is a re-emergent virus transmitted by two species of mosquitoes: Ae. Aegypti and Ae. Albopictus; 2) CHIKV caused massive outbreaks in LA; 3) Chronic CHIKV infection produces an inflammatory joint disease that in some cases can last several months to years, and 4) Currently, there are no vaccines or antivirals available for CHIKV infections. <h3>Conclusions</h3> PANLAR-ACCAR achieve 13 recommendations on CHIK categorised in three groups: 1) epidemiology and clinical manifestations; 2) diagnosis, and 3) treatment, representing the consensus agreement from the panel’s members. <h3>References</h3> [1] Pineda C, Munoz-Louis R, Caballero-Uribe CV, Viasus D. Chikungunya in the region of the Americas. A challenge for rheumatologists and health care systems. Clin Rheumatol2016;35(10):2381–5. [2] Fernandez-Salas I, Danis-Lozano R, Casas-Martinez M, Ulloa A, Bond JG, Marina CF, et al. Historical inability to control Aedes aegypti as a main contributor of fast dispersal of chikungunya outbreaks in Latin America. Antiviral Res2015;124:30–42. [3] Khoury VJ, Camilo PR. Chikungunya virus (CHIKV): what can be expected after the acute phase?Reumatol Clin2016;12(1):1–3. [4] JC Rueda, J-I Angarita, AM Santos, E-L Saldarriaga, I Pelaez-Ballestas, MJ Soares-Santeugini, J Londono. SAT0576 [5] Improved clinical scenario for chikungunya diagnosis Annals of the Rheumatic Diseases2017Jun;76(Suppl 2):994. <h3>Disclosure of Interest</h3> None declared